Evidence profile
LL-37 (10 mg Vial)
Human LL-37 studies reviewed here evaluate local treatment of specific wounds. Their findings are mixed and should remain tied to those settings.
01
Product identity
Topical wound formulations are different from a reconstituted injectable vial.
02
What has been studied
Primary human study
Venous leg ulcers
- Population or model
- 148 people with difficult-to-heal venous leg ulcers
- Study route or material
- Topical with compression therapy
In a 148-person phase 2b trial, topical LL-37 with compression therapy did not significantly improve healing overall. An exploratory subgroup finding in larger wounds needs a confirmatory study.[1]
Primary human study
Diabetic foot ulcers
- Population or model
- People with mildly infected diabetic foot ulcers
- Study route or material
- Topical cream
A separate cream study reported better granulation/healing measures, without significant improvements in the measured inflammatory markers or bacterial counts.[2]
03
Evidence limits
The reviewed studies do not establish a systemic injection dose or general immune-support use.
The reviewed sources do not establish patient instructions for this product. No dose, cycle, preparation method or administration schedule is provided here.
04
Formulation and handling evidence
Actual vial content and source label.
Exact formulation and intended research route; topical results do not establish injectable compatibility.
A compatible diluent, prepared-solution stability and container/device compatibility must be supported for the exact formulation. The diluent manufacturer’s instructions do not supply a universal storage period for every dissolved substance.[4]
05
Approval context
This profile has not established Canadian authorization of the linked research product.[3]
06
Sources and review scope
- LL-37 trial in difficult-to-heal venous leg ulcersPrimary human study · Abstract and indexed identity · Checked 2026-09-08
- LL-37 cream trial in diabetic foot ulcersPrimary human study · Abstract and indexed identity · Checked 2026-09-08
- Health Canada: unauthorized injectable peptide productsRegulatory advisory · Fresh Health Canada advisory read, including product/DIN and RUO-label limits · Checked 2026-09-09
- Hospira/Pfizer: bacteriostatic water manufacturer informationManufacturer information; US presentation · Fresh manufacturer page, relevant compatibility/storage/supply passages · Checked 2026-09-09
- Amino Labs: LL-37 | 10mgSupplier listing; identity reference · Exact heading, SKU, form and supplier URL from the full catalogue capture; not stock-lot authentication · Checked 2026-09-09
This is a selected-source evidence summary. It is not a systematic review, formal certainty grade or qualified clinical sign-off. Study dates and source-check dates are distinct.